Analyze Diet
Equine veterinary journal2012; 45(2); 235-239; doi: 10.1111/j.2042-3306.2012.00605.x

Accelerated vaccination schedule provides protective levels of antibody and complete herd immunity to equine influenza.

Abstract: During the 2007 Australian equine influenza (EI) outbreak, an accelerated primary course 14 day intervaccination schedule was proposed, but not widely implemented. Expert opinion was divided as to the efficacy of such a schedule given the lack of published data. This study determined the level and duration of humoral immunity following administration of a recombinant canarypox-vectored vaccine (ALVAC-EIV) with a primary intervaccination interval of 14 days and booster at 105 days. Objective: To examine whether protective levels of immunity of adequate duration were achieved following a primary course reduced from a minimum interval of 28 to 14 days. Antibody responses to 2 H3N8 American lineage virus strains (including A/equine/Sydney/6085/2007) were assessed and compared to previous challenge studies using ALVAC-EIV at conventional intervaccination intervals. Methods: Fourteen Thoroughbred horses and 2 ponies from a rural racehorse training property in Victoria, Australia, were vaccinated with ALVAC-EIV on Days 0, 14 and 105. Serial blood samples were collected over the next 32 weeks and tested with haemagglutination inhibition and single radial haemolysis (SRH) in full assays to evaluate the serological response. Results: All horses and ponies responded to the accelerated ALVAC-EIV vaccination schedule. Mean SRH antibodies remained above those consistent with clinical protection for the duration of the study period. All vaccinates demonstrated high SRH antibodies 14 days following V2, thereby achieving 100% herd immunity to homologous viral challenge. Conclusions: An accelerated vaccination schedule conferred long-lasting protective antibody levels despite a >50% reduction in the recommended V1-V2 interval. Conclusions: High levels of rapidly acquired herd immunity are critical in containing an outbreak of such a highly contagious pathogen as EIV. In a strategic vaccination programme, it is important that horses remain protected for sufficient time to allow control programmes to succeed. An accelerated 14 day primary course intervaccination interval and booster at 105 days achieves both of these objectives.
Publication Date: 2012-09-04 PubMed ID: 22943193DOI: 10.1111/j.2042-3306.2012.00605.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research paper studies the efficacy of an accelerated vaccination schedule against equine influenza. The researchers found that a rapid 14-day primary course of vaccination resulted in prolonged immunity and complete herd protection.

Objective of the Research

  • The research aimed to evaluate the effectiveness of a speedy vaccination schedule for equine influenza. The schedule reduced the primary course from a customary interval of 28 days to 14 days. The researchers then measured the antibody response and duration of immunity achieved.

Methodology and Testing

  • A group of 14 Thoroughbred horses and 2 ponies from Victoria, Australia, were chosen for this study. They were vaccinated with ALVAC-EIV on Days 0, 14, and 105.
  • Serial blood sampling was carried out over 32 weeks after vaccination. These samples were screened to assess the immune response against two H3N8 American lineage virus strains, which included A/equine/Sydney/6085/2007.
  • Two assay methods, haemagglutination inhibition and single radial haemolysis (SRH), were employed to explore the serological response.

Results of the Study

  • All the horses and ponies responded to the quickened ALVAC-EIV vaccination schedule.
  • The horses maintained an average SRH antibody response above the level consistent with clinical protection throughout the research period.
  • All the vaccinated horses and ponies displayed high SRH antibodies within 14 days post V2, achieving complete herd immunity against the homologous viral challenge.

Conclusions of the Study

  • The accelerated vaccination schedule resulted in sustainably protective antibody levels, despite more than 50% reduction in the typical V1-V2 interval.
  • High levels of rapidly achieved herd immunity are crucial to successfully control an outbreak of a highly infectious virus such as equine influenza.
  • In a systematic vaccination program, it is significant that horses are protected for a sufficient time frame to allow control strategies to succeed. The study demonstrated that an expedited 14-day primary course intervaccination interval and booster at 105 days achieved both these objectives.

Cite This Article

APA
El-Hage CM, Savage CJ, Minke JM, Ficorilli NP, Watson J, Gilkerson JR. (2012). Accelerated vaccination schedule provides protective levels of antibody and complete herd immunity to equine influenza. Equine Vet J, 45(2), 235-239. https://doi.org/10.1111/j.2042-3306.2012.00605.x

Publication

ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 45
Issue: 2
Pages: 235-239

Researcher Affiliations

El-Hage, C M
  • The Centre for Equine Infectious Diseases, Veterinary Pre-Clinical Centre, University of Melbourne, Victoria, Australia.
Savage, C J
    Minke, J M
      Ficorilli, N P
        Watson, J
          Gilkerson, J R

            MeSH Terms

            • Animals
            • Antibodies, Viral / blood
            • Horse Diseases / prevention & control
            • Horses
            • Immunization Schedule
            • Influenza Vaccines / administration & dosage
            • Influenza Vaccines / immunology
            • Orthomyxoviridae Infections / prevention & control
            • Orthomyxoviridae Infections / veterinary
            • Vaccination

            Citations

            This article has been cited 9 times.
            1. Pusterla N, James K, Barnum S, Bain F, Barnett DC, Chappell D, Gaughan E, Craig B, Schneider C, Vaala W. Frequency of Detection and Prevalence Factors Associated with Common Respiratory Pathogens in Equids with Acute Onset of Fever and/or Respiratory Signs (2008-2021). Pathogens 2022 Jul 2;11(7).
              doi: 10.3390/pathogens11070759pubmed: 35890002google scholar: lookup
            2. El-Hage C, Hartley C, Savage C, Watson J, Gilkerson J, Paillot R. Assessment of Humoral and Long-Term Cell-Mediated Immune Responses to Recombinant Canarypox-Vectored Equine Influenza Virus Vaccination in Horses Using Conventional and Accelerated Regimens Respectively. Vaccines (Basel) 2022 May 26;10(6).
              doi: 10.3390/vaccines10060855pubmed: 35746463google scholar: lookup
            3. van Diepen M, Chapman R, Douglass N, Whittle L, Chineka N, Galant S, Cotchobos C, Suzuki A, Williamson AL. Advancements in the Growth and Construction of Recombinant Lumpy Skin Disease Virus (LSDV) for Use as a Vaccine Vector. Vaccines (Basel) 2021 Oct 4;9(10).
              doi: 10.3390/vaccines9101131pubmed: 34696239google scholar: lookup
            4. Dilai M, Piro M, El Harrak M, Fougerolle S, Dehhaoui M, Dikrallah A, Legrand L, Paillot R, Fassi Fihri O. Impact of Mixed Equine Influenza Vaccination on Correlate of Protection in Horses. Vaccines (Basel) 2018 Oct 4;6(4).
              doi: 10.3390/vaccines6040071pubmed: 30287762google scholar: lookup
            5. Paillot R, Garrett D, Lopez-Alvarez MR, Birand I, Montesso F, Horspool L. The Immunity Gap Challenge: Protection against a Recent Florida Clade 2 Equine Influenza Strain. Vaccines (Basel) 2018 Jul 2;6(3).
              doi: 10.3390/vaccines6030038pubmed: 30004410google scholar: lookup
            6. Paillot R, El-Hage CM. The Use of a Recombinant Canarypox-Based Equine Influenza Vaccine during the 2007 Australian Outbreak: A Systematic Review and Summary. Pathogens 2016 Jun 10;5(2).
              doi: 10.3390/pathogens5020042pubmed: 27294963google scholar: lookup
            7. Paillot R. A Systematic Review of Recent Advances in Equine Influenza Vaccination. Vaccines (Basel) 2014 Nov 14;2(4):797-831.
              doi: 10.3390/vaccines2040797pubmed: 26344892google scholar: lookup
            8. Galvin P, Gildea S, Arkins S, Walsh C, Cullinane A. The evaluation of a nucleoprotein ELISA for the detection of equine influenza antibodies and the differentiation of infected from vaccinated horses (DIVA). Influenza Other Respir Viruses 2013 Dec;7 Suppl 4(Suppl 4):73-80.
              doi: 10.1111/irv.12195pubmed: 24224822google scholar: lookup
            9. Gonzalez-Obando J, Jaimes-Dueñez J, Zuluaga-Cabrera A, Forero JE, Diaz A, Rojas-Arbeláez C, Ruiz-Saenz J. Seroprevalence of Equine Influenza Virus Antibodies in Horses from Four Localities in Colombia. Viruses 2025 Jul 16;17(7).
              doi: 10.3390/v17070999pubmed: 40733615google scholar: lookup